Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.3954 -0.0046 (-1.15%)
Streaming Delayed Price Updated: 2:05 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
News headline image
Sangamo's Fabry Disease Gene Therapy Continues To Show Encouraging Safety Profile ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 22, 2023 ↗
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
News headline image
Earnings Preview For Sangamo Therapeutics ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week ↗
These cutting-edge biotech companies quickly fell out of favor with investors this week. 
Via The Motley Fool
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 152 stocks made new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 258 companies hit new 52-week lows. 
Via Benzinga
News headline image
Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment ↗
Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, 
Via Benzinga
News headline image
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
News headline image
Earnings Scheduled For November 3, 2022 ↗
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
News headline image
Sangamo Therapeutics's Earnings Outlook ↗
Sangamo Therapeutics (NASDAQ:SGMO) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Touts Additional Positive Data For Fabry Gene Therapy Candidate ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical Hold ↗
 
Via Benzinga
News headline image
Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions ↗
As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a... 
Via Benzinga
News headline image
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics's Return On Capital Employed Insights ↗
According to data from Benzinga Pro, during Q2, Sangamo Therapeutics's (NASDAQ:SGMO) reported sales totaled $29.38 million. Despite a 1.83% increase in earnings, the company posted a loss of $43.17... 
Via Benzinga
News headline image
Recap: Sangamo Therapeutics Q2 Earnings ↗
Sangamo Therapeutics (NASDAQ:SGMO) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
From Sangamo Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Talis Biomedical (NASDAQ:TLIS) shares moved upwards by 10.6% to $0.94 during Tuesday's after-market session. The company's market cap stands at $25.0 million. 
Via Benzinga
News headline image
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
From Sangamo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.